Monte Rosa Therapeutics Inc (GLUE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $800.67M
Last updated: Nov 17, 2026 at 11:05 AM ET
Monte Rosa Therapeutics Inc (GLUE) Financials: Revenue, Profit and Cash Flow
Monte Rosa Therapeutics reported revenue of $123.67M for the fiscal year ended Dec 31, 2025, up 63.5% from the year before. That year, net income was -$38.63M with a net margin of -31.2%, operating cash flow was -$22.80M and free cash flow was -$27.50M. The quarter ended Sep 30, 2026 had revenue of $54.37M and net income of $3.06M.
Revenue and Margins
The operating margin was -43.8% in the fiscal year ended Dec 2025.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $123.67M | +63.5% | 100.0% | -43.8% | -31.2% |
| Dec 2024 | $75.62M | N/A | 100.0% | -107.3% | -96.1% |
| Dec 2023 | $0 | N/A | N/A | N/A | N/A |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $123.67M | $75.62M | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $72.00K |
| Gross profit | $123.67M | $75.62M | $0 | $0 | $0 | $0 | -$72.00K |
| Research and development | $141.50M | $121.56M | $111.27M | $85.06M | $57.16M | $24.00M | $7.35M |
| Operating income | -$54.21M | -$81.11M | -$143.31M | -$112.38M | -$72.88M | -$28.01M | -$7.99M |
| Net income | -$38.63M | -$72.70M | -$135.35M | -$108.50M | -$73.96M | -$35.88M | -$8.02M |
| EBITDA | -$44.31M | -$72.58M | -$138.00M | -$108.52M | -$71.87M | N/A | -$7.67M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.37M | $8.97M | $4.21M | $2.78M | $12.77M | $23.19M | $84.93M | $60.65M | $9.22M | $4.70M | $1.06M | $8.75M |
| Gross profit | $54.37M | $8.97M | $4.21M | $2.78M | $12.77M | $23.19M | $84.93M | $60.65M | $9.22M | $4.70M | $1.06M | -$1.85M |
| Operating income | -$1.94M | -$49.13M | -$50.03M | -$49.72M | -$32.98M | -$15.55M | $44.04M | $13.00M | -$26.53M | -$32.64M | -$34.95M | -$34.86M |
| Net income | $3.06M | -$43.40M | -$44.50M | -$46.13M | -$27.08M | -$12.29M | $46.88M | $13.44M | -$23.86M | -$30.31M | -$31.97M | -$33.25M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $4.40M by $125.49M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $448.66M | $438.73M | $303.75M | $342.39M | $366.33M | $49.38M | $11.09M |
| Current assets | $393.19M | $377.44M | $236.21M | $275.89M | $348.67M | $43.59M | $9.76M |
| Cash and equivalents | $129.88M | $224.25M | $128.10M | $54.91M | $346.07M | $41.70M | $6.00M |
| Total liabilities | $215.60M | $215.80M | $124.50M | $70.98M | $18.81M | $30.34M | $23.24M |
| Short-term debt | $4.40M | $3.71M | $3.16M | $3.13M | N/A | N/A | $750.00K |
| Shareholder equity | $233.06M | $222.94M | $179.25M | $271.41M | $347.51M | $48.73M | -$12.15M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $697.73M | $691.16M | $736.43M | $448.66M | $459.84M | $359.59M | $393.20M | $438.73M | $315.08M | $344.11M | $266.75M | $303.75M |
| Total liabilities | $201.52M | $203.88M | $214.51M | $215.60M | $214.00M | $91.51M | $118.04M | $215.80M | $109.62M | $119.44M | $114.23M | $124.50M |
| Cash and equivalents | $45.18M | $90.10M | $159.86M | $129.88M | $208.34M | $69.43M | $78.53M | $224.25M | $125.58M | $108.85M | $99.75M | $128.10M |
| Shareholder equity | $496.21M | $487.28M | $521.92M | $233.06M | $245.84M | $268.08M | $275.16M | $222.94M | $205.46M | $224.67M | $152.52M | $179.25M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22.80M | $42.00M | -$43.80M | -$92.47M | -$59.36M | -$23.05M | -$6.17M |
| Capital expenditures | $4.70M | $3.99M | $19.04M | $12.91M | $9.73M | $3.39M | $1.39M |
| Free cash flow | -$27.50M | $38.01M | -$62.84M | -$105.38M | -$69.09M | -$26.44M | -$7.56M |
| Share repurchases | $357.00K | $641.00K | $116.00K | $364.00K | $231.00K | $440.00K | N/A |
| Investing cash flow | -$101.83M | -$44.45M | $88.80M | -$219.22M | -$9.65M | -$3.39M | -$1.39M |
| Financing cash flow | $30.35M | $98.89M | $27.49M | $20.47M | $377.56M | $60.06M | $15.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$40.98M | -$44.11M | -$37.37M | -$43.01M | $100.43M | -$34.72M | -$45.49M | $128.92M | -$20.99M | -$27.77M | -$38.16M | $29.63M |
| Capital expenditures | $1.56M | $4.72M | $1.87M | $767.00K | $651.00K | $1.70M | $1.59M | $183.00K | $399.00K | $2.02M | $1.38M | $1.69M |
| Free cash flow | -$42.54M | -$48.84M | -$39.24M | -$43.78M | $99.78M | -$36.41M | -$47.08M | $128.74M | -$21.39M | -$29.79M | -$39.55M | $27.95M |
Frequently Asked Questions About GLUE
What is Monte Rosa Therapeutics' annual revenue?
Monte Rosa Therapeutics reported revenue of $123.67M for the fiscal year ended Dec 31, 2025.
How fast is Monte Rosa Therapeutics' revenue growing?
Revenue was up 63.5% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is Monte Rosa Therapeutics profitable?
No. Monte Rosa Therapeutics reported net income of -$38.63M for the fiscal year ended Dec 31, 2025, with a net margin of -31.2%.
How much free cash flow does GLUE generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$22.80M minus capital expenditures of $4.70M produced free cash flow of -$27.50M.
How much debt does Monte Rosa Therapeutics have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $4.40M and cash and equivalents of $129.88M.
GLUE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors